PI4K2A: a novel potential therapeutic target for lung cancer
Camila Machado Baldavira,Tabatha Gutierrez Prieto,Maria Aparecida Nagai,Vera Luiza Capelozzi
DOI: https://doi.org/10.21037/tlcr-23-734
2024-01-31
Translational Lung Cancer Research
Abstract:Camila Machado Baldavira 1^ , Tabatha Gutierrez Prieto 1^ , Maria Aparecida Nagai 2,3^ , Vera Luiza Capelozzi 1^ 1 Department of Pathology, Medical School, University of São Paulo (USP), São Paulo, Brazil; 2 Department of Radiology and Oncology, Medical School, University of São Paulo (USP), São Paulo, Brazil; 3 Laboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of São Paulo (ICESP), São Paulo, Brazil ^ ORCID: Camila Machado Baldavira, 0000-0002-5364-7305; Tabatha Gutierrez Prieto, 0000-0002-2615-6922; Maria Aparecida Nagai, 0000-0002-0728-4937; Vera Luiza Capelozzi, 0000-0001-9732-5853. Comment on: Tan X, Xiao GY, Wang S, et al . EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer. J Clin Invest 2023;133:e165863. Keywords: PI4K2A ; malignant hypersecretion; Golgi apparatus; epithelial-mesenchymal transition (EMT); non-small cell lung cancer (NSCLC) Submitted Nov 11, 2023. Accepted for publication Dec 19, 2023. Published online Jan 12, 2024. doi: 10.21037/tlcr-23-734 Despite the advances in precision medicine, invasion, and metastasis continue to be the leading causes of cancer-related deaths. A better comprehension of the disease progression will decide new therapeutic strategies. Non-small cell lung cancer (NSCLC) is the deadliest cancer worldwide, primarily because of its high tendency to invade and metastasize (1). Therefore, preventing or treating metastasis is vital for ameliorating survival but requires a profound knowledge of the underlying drivers and pathways (2). The tumor microenvironment (TME) is a critical component in cancer implicated in tumorigenesis and metastasis. Recently, it has been proposed that secreted peptides by malignant cells play a crucial role in triggering TME factors that favor invasion and metastasis (3). Among these factors, collagenase remodels collagen fibers, increasing stromal stiffness and facilitating cancer cell mobilization for invasion (4). However, clinical investigations targeting secreted peptides in the TME, such as matrix metalloproteinases (MMPs), did not demonstrate robust anti-cancer regression (5), contributing more as a physical and biochemical barrier, preventing drug assessment and immune response. Moreover, acquired insights have linked genetic drivers and inflammation to the abnormal initiation of an epigenetic process known as the epithelial-mesenchymal transition (EMT), which confers metastatic ability to tumor cells (6) and resistance to therapy (7). EMT is a complex program modulated by multiple transcription factors, post-translational events, epigenetic modifications, and noncoding RNA-mediated regulation. Activation of EMT facilitates the replacement of polarized epithelial cells phenotype toward a mesenchymal phenotype, followed by the loss of epithelial characteristics, apicobasal polarity, intercellular junctions, and acquisition of inherent migratory and invasive traits (6). Together, genetic drivers of metastasis and epigenetic mechanisms related to EMT induce cancer invasion endowing elasticity and complacence to malignant cells, improving their survival throughout the metastatic journey (6). Kundu and colleagues have demonstrated that the metastatic sequence and EMT are initiated by the loss of miR-200 and miR-96 in epithelial cells, allowing their ZEB1 and FOXF2 targets to activate mesenchymal cells to drive metastasis (8). However, inhibiting ZEB1 or adding microRNAs (miRNAs) to control EMT for treating metastasis has proven to be a therapeutic challenge (8). This indicates that new experiments are necessary to dissect the EMT downstream pathway to inhibit metastasis and mesenchymal cells. In this regard, researchers have studied vesicle traffic of intracellular proteins to drive the malignant secretion of extracellular matrix-modifying factors leading to invasive tumor cell behavior (9-11). Considering the recent study published by Tan et al. (11) brings out new information into the mechanisms that EMT coordinates exocytic and endocytic vesicular trafficking impacting NSCLC recurrence and metastatic progression. They identify the PI4K2A a membrane-associated RNA-dependent protein kinase, as a key player in cell signaling and vesicle trafficking, as a promise therapeutically actionable driver of lung cancer progression. PI4K2A kinase expression has long been associated with human diseases, including cancer, immunodeficiencies, viral infection, and neurodegenerative diseases (12,13). Nevertheless, its involvement in lung cancer has not been fully investigated. Of note, previous studies showed that the submicroscopic Golgi organelle functions are modulated -Abstract Truncated-
oncology,respiratory system